TEKLA CAPITAL MANAGEMENT LLC
Q2 2023 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001300336
· CRD 119626
· SEC-registered investment adviser
$2.6B Reported Value Total
TEKLA CAPITAL MANAGEMENT LLC reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $3,218,121,570, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Source: Form ADV filed 2023-03-29
Reported value
$2.6B
Quarter over quarter
+1.1%
Holdings
166
Top-10 concentration
40.3%
Key People
Form ADV owners & control persons
Daniel R Omstead
PRESIDENT, CEO, CFO, MEMBER AND MANAGER
Mary N Omstead
MEMBER
Laura F Woodward
CHIEF COMPLIANCE OFFICER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q2 2023 13F record
Q2 2023 13F filing summary
| Period of report | June 30, 2023 |
|---|---|
| Filed | August 10, 2023 |
| Form | 13F-HR |
| Reported value | $2.6B |
| Positions | 166 |
| Change in reported value | -2.7% |
| New positions | 9 |
| Exited positions | 20 |
| Position turnover | 15.6% |
| Top-10 concentration | 40.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2023 13F
Filed Aug 10, 2023
|
166 | $2.6B |
|
Q1 2023 13F
Filed May 10, 2023
|
177 | $2.6B |
|
Q4 2022 13F
Filed Feb 10, 2023
|
172 | $2.6B |
|
Q3 2022 13F
Filed Nov 1, 2022
|
168 | $2.4B |
|
Q2 2022 13F
Filed Jul 29, 2022
|
177 | $2.5B |
|
Q1 2022 13F
Filed May 13, 2022
|
175 | $2.8B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
171 | $3.1B |
|
Q3 2021 13F
Filed Nov 12, 2021
|
172 | $3.1B |
|
Q2 2021 13F
Filed Aug 13, 2021
|
189 | $3.1B |
|
Q1 2021 13F
Filed May 14, 2021
|
196 | $2.9B |
|
Q4 2020 13F
Filed Feb 12, 2021
|
200 | $2.8B |
|
Q3 2020 13F
Filed Nov 13, 2020
|
204 | $2.7B |
|
Q2 2020 13F
Filed Aug 13, 2020
|
222 | $2.6B |
|
Q1 2020 13F
Filed May 14, 2020
|
217 | $2.2B |
|
Q4 2019 13F
Filed Feb 13, 2020
|
214 | $2.6B |
|
Q3 2019 13F
Filed Nov 13, 2019
|
192 | $2.3B |
|
Q2 2019 13F
Filed Aug 14, 2019
|
197 | $2.5B |
|
Q1 2019 13F
Filed May 14, 2019
|
194 | $2.5B |
|
Q4 2018 13F
Filed Feb 13, 2019
|
201 | $2.3B |
|
Q3 2018 13F
Filed Nov 13, 2018
|
210 | $2.8B |
21 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | AMGN Amgen Inc. | $136.9M | 5.36% |
| 2 | JNJ Johnson & Johnson | $119.5M | 4.68% |
| 3 | GILD Gilead Sciences, Inc. | $118.2M | 4.63% |
| 4 | REGN Regeneron Pharmaceuticals, Inc. | $116.0M | 4.54% |
| 5 | VRTX Vertex Pharmaceuticals Inc. | $111.9M | 4.38% |
| 6 | LLY Eli Lilly and Company | $100.1M | 3.92% |
| 7 | UNH Unitedhealth Group Inc. | $99.5M | 3.89% |
| 8 | MRK Merck & Co., Inc. | $84.0M | 3.29% |
| 9 | ABBV AbbVie Inc. | $73.5M | 2.88% |
| 10 | BIIB Biogen Inc. | $70.6M | 2.76% |
| 11 | AZN AstraZeneca PLC | $69.9M | 2.74% |
| 12 | ILMN Illumina, Inc. | $63.2M | 2.47% |
| 13 | ABT Abbott Laboratories | $60.2M | 2.36% |
| 14 | PFE Pfizer Inc. | $59.6M | 2.33% |
| 15 | TMO Thermo Fisher Scientific Inc. | $51.6M | 2.02% |
| 16 | ELV Elevance Health, Inc. | $50.7M | 1.98% |
| 17 | MRNA Moderna, Inc. | $41.8M | 1.63% |
| 18 | BSX Boston Scientific Corp. | $35.6M | 1.39% |
| 19 | DHR Danaher Corp. | $34.3M | 1.34% |
| 20 | MDT Medtronic plc | $30.3M | 1.19% |
Values as reported on the Q2 2023 Form 13F. Every position is in the holdings table below.